ZIOPHARM Oncology Inc. (ZIOP) Reaches $4.19 After 4.00% Down Move; Garrison Capital (GARS) Shorts Lowered By 19.4%

November 14, 2017 - By Marie Mckinney

The stock of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) is a huge mover today! About 707,675 shares traded. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has risen 1.75% since November 14, 2016 and is uptrending. It has underperformed by 14.95% the S&P500.The move comes after 9 months negative chart setup for the $594.97M company. It was reported on Nov, 14 by Barchart.com. We have $4.02 PT which if reached, will make NASDAQ:ZIOP worth $23.80 million less.

Garrison Capital Incorporated (NASDAQ:GARS) had a decrease of 19.4% in short interest. GARS’s SI was 18,700 shares in November as released by FINRA. Its down 19.4% from 23,200 shares previously. With 29,800 avg volume, 1 days are for Garrison Capital Incorporated (NASDAQ:GARS)’s short sellers to cover GARS’s short positions. About 19,606 shares traded. Garrison Capital Inc (NASDAQ:GARS) has declined 12.87% since November 14, 2016 and is downtrending. It has underperformed by 29.57% the S&P500.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The company has market cap of $594.97 million. The Firm is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral therapies for the treatment of cancer and graft-versus-host-disease. It currently has negative earnings. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System expression platform.

Analysts await ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to report earnings on February, 15. They expect $-0.13 EPS, down 18.18% or $0.02 from last year’s $-0.11 per share. After $-0.13 actual EPS reported by ZIOPHARM Oncology Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Among 4 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Ziopharm Oncology had 6 analyst reports since December 4, 2015 according to SRatingsIntel. As per Wednesday, May 11, the company rating was maintained by Mizuho. Mizuho maintained the stock with “Neutral” rating in Monday, January 25 report. The stock of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) earned “Underperform” rating by Wells Fargo on Friday, December 4. The rating was initiated by Raymond James on Thursday, June 2 with “Market Perform”. Wells Fargo upgraded the stock to “Market Perform” rating in Wednesday, August 10 report.

Garrison Capital Inc. is a managed, closed-end, non-diversified management investment company. The company has market cap of $132.41 million. The Company’s investment objective is to generate current income and capital appreciation by making investments primarily in debt securities and loans of the United States middle-market companies, which it defines as those having annual earnings before interest, taxes and depreciation, or EBITDA, of certain amount. It has a 24.69 P/E ratio. It invests or provides direct lending in first lien senior secured loans, second lien senior secured loans, one-stop senior secured loans or unitranche loans, subordinated or mezzanine loans, unsecured consumer loans and to a lesser extent, selected equity co-investments in middle-market companies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.